

Special Issue

Recent Advances on Coronavirus Disease 2019 (COVID-19)

Message from the Guest Editors

For more than a year now, the world has been facing one of the most aggressive pandemics it has ever known. Numerous discoveries have led to progress in understanding, treating, and preventing COVID-19 infection, but there are still many grey areas that need to be addressed to better understand this disease. This Special Issue of the *Journal of Personalized Medicine* aims to highlight the current state of the science and showcase some of the latest findings in the field of COVID-19. Research on COVID-19 must be an international priority in view of the human and economic implications of the pandemic.

Guest Editors

Prof. Dr. Patrick Plaisance

Emergency Department and PreHospital Care, Hôpital Lariboisière,
University of Paris, Paris, France

Dr. Anthony Chauvin

Emergency Department and PreHospital Care, Hôpital Lariboisière,
University of Paris, Paris, France

Deadline for manuscript submissions

closed (25 April 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/91134

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

[jpm](https://www.mdpi.com/journal/jpm)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

[jpm](https://jpm.mdpi.com)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).